Advanced

Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study

Braconier, Jean Henrik LU ; Paulsen, Otto; Engman, Katarina and Widell, Anders LU (1995) In Scandinavian Journal of Infectious Diseases 27(4). p.325-329
Abstract
16 patients with chronic hepatitis C virus (HCV) infection were treated with a combination of interferon-alpha and ribavirin for 24 weeks in an open study. One patient declined further treatment due to depression after week 16 and did not complete further follow-up. A moderate decline was observed in hemoglobin and an increase in bilirubin level both reversible after discontinuing the treatment. 24 weeks after treatment cessation 9/15 (60%) evaluable patients had complete clearance of HCV-RNA as measured with PCR. HCV genotype did not seem to be correlated with response, but patients with sustained response to treatment had a significantly reduced number of HCV RNA copies/ml serum at treatment start compared with the other patients. These... (More)
16 patients with chronic hepatitis C virus (HCV) infection were treated with a combination of interferon-alpha and ribavirin for 24 weeks in an open study. One patient declined further treatment due to depression after week 16 and did not complete further follow-up. A moderate decline was observed in hemoglobin and an increase in bilirubin level both reversible after discontinuing the treatment. 24 weeks after treatment cessation 9/15 (60%) evaluable patients had complete clearance of HCV-RNA as measured with PCR. HCV genotype did not seem to be correlated with response, but patients with sustained response to treatment had a significantly reduced number of HCV RNA copies/ml serum at treatment start compared with the other patients. These findings support the promising results of this combination therapy noted in other pilot studies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Scandinavian Journal of Infectious Diseases
volume
27
issue
4
pages
325 - 329
publisher
Informa Healthcare
external identifiers
  • pmid:8658064
  • scopus:0029120899
ISSN
1651-1980
DOI
10.3109/00365549509032725
language
English
LU publication?
yes
id
801bc9bc-af9e-47ce-8108-8427edfa5d45 (old id 1108814)
date added to LUP
2008-07-24 16:47:08
date last changed
2017-04-30 14:27:49
@article{801bc9bc-af9e-47ce-8108-8427edfa5d45,
  abstract     = {16 patients with chronic hepatitis C virus (HCV) infection were treated with a combination of interferon-alpha and ribavirin for 24 weeks in an open study. One patient declined further treatment due to depression after week 16 and did not complete further follow-up. A moderate decline was observed in hemoglobin and an increase in bilirubin level both reversible after discontinuing the treatment. 24 weeks after treatment cessation 9/15 (60%) evaluable patients had complete clearance of HCV-RNA as measured with PCR. HCV genotype did not seem to be correlated with response, but patients with sustained response to treatment had a significantly reduced number of HCV RNA copies/ml serum at treatment start compared with the other patients. These findings support the promising results of this combination therapy noted in other pilot studies.},
  author       = {Braconier, Jean Henrik and Paulsen, Otto and Engman, Katarina and Widell, Anders},
  issn         = {1651-1980},
  language     = {eng},
  number       = {4},
  pages        = {325--329},
  publisher    = {Informa Healthcare},
  series       = {Scandinavian Journal of Infectious Diseases},
  title        = {Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study},
  url          = {http://dx.doi.org/10.3109/00365549509032725},
  volume       = {27},
  year         = {1995},
}